Business
Medicenna Reports Third Quarter Fiscal 2020 Financial Results
Medicenna Reports Third Quarter Fiscal 2020 Financial Results Canada NewsWire TO...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Reports Third Quarter Fiscal 2020 Financial Results\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, Feb. 13, 2020\n\n\n\nTORONTO and HOUSTON, Feb. 13, 2020 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or the \"Company\") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, today reported financial results for the three and nine months ended December 31, 2019. The Company's fiscal Q3 2020 interim financial statements and MD&A will be available on SEDAR.\n\"We have achieved a number of exciting and important milestones this quarter, both in the ongoing development of MDNA55 and MDNA19 and in further strengthening our financial position as we swiftly advance towards the important End of Phase 2 meeting with the FDA this spring,\" said Dr. Fahar Merchant, President and CEO, Medicenna Therapeutics. \"We've documented exceptional survival advantage rates with MDNA55 in patients with the most difficult to treat form of brain cancer when compared to today's commonly used treatments, and will have key non-human primate data for MDNA19 this quarter as we accelerate development of our second important asset. Recent acquisitions in the space are further evidence that Medicenna is ideally positioned in a market that is growing in both opportunity and value, as major pharmaceutical companies recognize the necessity of novel IL2 assets like MDNA19 to support their cancer portfolio.\" \nThe following are the achievements and highlights for the quarter ending December 31, 2019, through to the date hereof:\nOn January 13, 2020, Medicenna announced results from a retrospective study of subjects with recurrent glioblastoma (\"rGBM\") receiving standard therapies who matched eligibility requirements of subjects enrolled in the MDNA55-05 clinical trial (Synthetic Control Arm, or SCA), and compared their survival versus subjects treated with MDNA55 in the Phase 2b rGBM clinical trial. The SCA comprised of 81 rGBM patients receiving standard therapies, including Avastin, Lomustine and Temozolomide, with similar...